Home / Therapies / GLP-1 Agonist Therapy Center (page 6)

GLP-1 Agonist Therapy Center

GLP-1 Diabetes Drug Treatment: GLP-1 (glucagon-like peptide 1 receptor agonists) are incretin mimetics which have several benefits for diabetes management. They suppress post-prandial glucagon release, delay stomach emptying, and increase insulin sensitivity. Significantly lower rates of hypoglycemia accompany GLP-1 therapy. This class also has the side effect of modest weight reduction and reduction of systolic blood pressure. GLP-1 receptor agonists are counter-indicated for patients with a history of pancreatitis.

Liraglutide Lacks HbA1c Control in Type 1 Diabetes

Jan 8, 2016 Type 1 Diabetes, Articles, GLP-1 Agonist Therapy Center

New study of normal-weight patients suggests weight reduction, insulin requirements.

Liraglutide Success Shown Dependent on Early Weight Loss

Jan 2, 2016 Obesity, Type 2 Diabetes, Articles, GLP-1 Agonist Therapy Center

Patients who responded to medication had greater improvement in cardiometabolic risk factors.

Study Shows Liraglutide Helps To Reduce Sleepiness

Jan 2, 2016 Obesity, Type 2 Diabetes, Articles, GLP-1 Agonist Therapy Center

Quality of life in obese patients with type 2 diabetes improved.

Risks and Benefits of GLP-1s

Dec 18, 2015 Type 2 Diabetes, Articles, GLP-1 Agonist Therapy Center

Systemic review, network meta-analysis found treatment resulted in greatest reductions in HbA1c, fasting blood glucose, and body weight.

Victoza Vs. SGLT-2 inhibitor for Better BG Control

Dec 18, 2015 Type 2 Diabetes, Articles, Blood Glucose Control, GLP-1 Agonist Therapy Center

Safety, efficacy of these new classes of diabetic medication require more detailed investigation.

The Present and Future of Insulin Therapy Part 19

Dec 7, 2015 Clinical Presentations, GLP-1 Agonist Therapy Center

In this week's Homerun Slides, the philosophy for the reduced need for insulin in type 2 patients and the potential benefits of combining GLP-1-based therapies with insulin.

Pancreatic Cancer Not Associated with Incretin Drugs

Nov 20, 2015 Oncology, Articles, DPP-4 Therapy Center, GLP-1 Agonist Therapy Center

Study results indicate that risk increased similarly for all glucose lowering agents.

The Present and Future of Insulin Therapy Part 14

Nov 3, 2015 Clinical Presentations, GLP-1 Agonist Therapy Center, Insulin Therapy Center

In this week's Homerun Slides, the effectiveness of Lixisenatide when added to basal insulin, and strategies for avoiding or minimizing the GI effects of GLP-1.

Lactobacillus reuteri Improves Incretin and Insulin Secretion

Oct 16, 2015 Articles, Diet & Nutrition, GLP-1 Agonist Therapy Center

Probiotic does not change insulin sensitivity in glucose-tolerant individuals.

Dr. Paresh Dandona, Part 1: GLP-1 Receptor Agonists as Adjunctive Treatment in Type 1 Diabetes

Oct 12, 2015 Exclusive Interviews, GLP-1 Agonist Therapy Center

Dr. Paresh Dandona, Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at the University of Buffalo, The State University of New York, joins Associate Medical Editor Joy Pape in a discussion at the 2015 ADA Sessions in Boston regarding highlights of his presentation, "GLP-1 Receptor Agonists as Adjunctive Treatment in Type 1 Diabetes."

Page 6 of 14« First...«4 567 8 » 10...Last »